- Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings The Wall Street Journal
- Vertex next-generation pain candidate fails Phase 2 trial statnews.com
- Vertex shares plummet 15% as next-gen painkiller misses target The Business Journals
- Vertex drops aspiring Journavx follower in acute pain after phase 2 failure Fierce Biotech
- Vertex’s pain portfolio is pummeled with setbacks FirstWord Pharma
Source link